Elevated IL-37 Levels in the Plasma of Patients with Severe Coronary Artery Calcification
Overview
Authors
Affiliations
Background: Coronary artery calcification (CAC) is a predictor of cardiovascular events and plaque burden and is closely associated with chronic inflammation. Interleukin (IL)-37 is a newly discovered member of the IL-1 family and is considered an anti-inflammatory cytokine. Our recent study on mice indicated that IL-37 could attenuate atherosclerosis and vascular calcification, which suggests that IL-37 could be associated with the development of atherosclerosis and related diseases. The aim of this study was to investigate if IL-37 plays a role in the progression of CAC in patients.
Methods: Two hundred participants with suspected cardiovascular disease were recruited. The levels of plasma IL-37, osteoprotegerin (OPG), hypersensitive C-reactive protein (hsCRP) together with other biochemical parameters were measured, and a coronary calcium assessment was carried out by multi-detector row CT. A score of < 10 AU (Agatston units) denotes an absence of CAC, a score of 11-100 AU denotes mild CAC, 101-400 denotes moderate CAC, and > 400 AU denotes severe CAC.
Results: Our initial data showed that there were no apparent differences in plasma IL-37 levels among patients with or without mild or moderate CAC. However, IL-37 levels were significantly increased in patients with severe CAC ( < 0.001). Similar results were observed for plasma OPG and hsCRP levels. When IL-37 levels in patients with severe calcification were compared with that in all of the other non-severe CAC groups, it became apparent that there was a significant positive correlation between IL-37 level and severe CAC ( = 0.360, < 0.001; OR = 1.033) using Spearman's correlation and binary logistic regression analysis.
Conclusions: This study demonstrates that the anti-inflammatory cytokine IL-37 is associated with high coronary calcium levels, suggesting that IL-37 expression may be caused by the activation of inflammation and that IL-37 might become a predictor of severe CAC in the future, which requires further investigation.
A review of cutting-edge biomarkers for diagnosing coronary artery disease.
Azami P, Mohammadzadeh S, Seirafi S, Razeghian-Jahromi I Medicine (Baltimore). 2025; 104(4):e41377.
PMID: 39854741 PMC: 11771658. DOI: 10.1097/MD.0000000000041377.
Zhu X, Meng X, Chen G, Su J, Fu X, Xu A Cell Commun Signal. 2024; 22(1):488.
PMID: 39394127 PMC: 11468037. DOI: 10.1186/s12964-024-01873-7.
Dong L, Tong J, Fan S Cardiovasc J Afr. 2023; 34(5):273-277.
PMID: 36637451 PMC: 11040466. DOI: 10.5830/CVJA-2022-056.
Interleukin-1 in Coronary Artery Disease.
Oikonomou E, Tsaplaris P, Anastasiou A, Xenou M, Lampsas S, Siasos G Curr Top Med Chem. 2022; 22(28):2368-2389.
PMID: 36263481 DOI: 10.2174/1568026623666221017144734.
Qin Y, Ren S, Shao B, Qin H, Wang H, Li G Front Immunol. 2022; 13:931783.
PMID: 35935954 PMC: 9354626. DOI: 10.3389/fimmu.2022.931783.